WO2013072705A1 - Muscarinic m1 receptor agonists - Google Patents
Muscarinic m1 receptor agonists Download PDFInfo
- Publication number
- WO2013072705A1 WO2013072705A1 PCT/GB2012/052857 GB2012052857W WO2013072705A1 WO 2013072705 A1 WO2013072705 A1 WO 2013072705A1 GB 2012052857 W GB2012052857 W GB 2012052857W WO 2013072705 A1 WO2013072705 A1 WO 2013072705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- compound
- ethyl
- carboxylate
- mmol
- Prior art date
Links
- 0 C*(CC(*)(CC1)C(NC)=O)CN1[C@@](CC1)C*(C)CCN1C(OC*)=O Chemical compound C*(CC(*)(CC1)C(NC)=O)CN1[C@@](CC1)C*(C)CCN1C(OC*)=O 0.000 description 1
- HOJZZUGXEMZVMT-AWEZNQCLSA-N CC(C)(C)OC(N(CCC1)CC[C@H]1N(CC1)CCC1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)CC[C@H]1N(CC1)CCC1C(O)=O)=O HOJZZUGXEMZVMT-AWEZNQCLSA-N 0.000 description 1
- HXHXCINOTMVCAO-SFHVURJKSA-N CC(C)CNC(C(CC1)CCN1[C@@H](CCC1)CCN1C(OC(C)(C)C)=O)=O Chemical compound CC(C)CNC(C(CC1)CCN1[C@@H](CCC1)CCN1C(OC(C)(C)C)=O)=O HXHXCINOTMVCAO-SFHVURJKSA-N 0.000 description 1
- IBUMPBFHLUYONP-UHFFFAOYSA-N CCOC(N(CCC1)CCC1=O)=O Chemical compound CCOC(N(CCC1)CCC1=O)=O IBUMPBFHLUYONP-UHFFFAOYSA-N 0.000 description 1
- SPABXNSWUFEDGB-UHFFFAOYSA-N CCOC(N(CCC1)CCC1N(CC1)CCC1(C(O)=O)F)=O Chemical compound CCOC(N(CCC1)CCC1N(CC1)CCC1(C(O)=O)F)=O SPABXNSWUFEDGB-UHFFFAOYSA-N 0.000 description 1
- HHKPCCFYUKWBCC-UHFFFAOYSA-N CCOC(N(CCC1)CCC1N(CC1)CCC1C(NCC(C)C)=O)=O Chemical compound CCOC(N(CCC1)CCC1N(CC1)CCC1C(NCC(C)C)=O)=O HHKPCCFYUKWBCC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- This invention relates to compounds that are agonists of the muscarinic M 1 receptor and which are useful in the treatment of muscarinic M 1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
- Muscarinic acetylcholine receptors are members of the G protein-coupled receptor superfamily which mediate the actions of the neurotransmitter acetylcholine in both the central and peripheral nervous system.
- Five mAChR subtypes have been cloned, Mi to M 5 .
- the Mi mAChR is predominantly expressed post-synaptically in the cortex, hippocampus, striatum and thalamus; M 2 mAChRs are located predominantly in the brainstem and thalamus, though also in the cortex, hippocampus and striatum where they reside on cholinergic synaptic terminals (Langmead et al. , 2008 Br J Pharmacol).
- M 2 mAChRs are also expressed peripherally on cardiac tissue (where they mediate the vagal innervation of the heart) and in smooth muscle and exocrine glands.
- M 3 mAChRs are expressed at relatively low level in the CNS but are widely expressed in smooth muscle and glandular tissues such as sweat and salivary glands (Langmead et al. , 2008 Br J Pharmacol).
- Muscarinic receptors in the central nervous system play a critical role in mediating higher cognitive processing.
- Diseases associated with cognitive impairments such as Alzheimer's disease, are accompanied by loss of cholinergic neurons in the basal forebrain (Whitehouse et al. , 1982 Science).
- schizophrenia which also has cognitive impairment as an important component of the clinical picture, mAChR density is reduced in the pre-frontal cortex, hippocampus and caudate putamen of schizophrenic subjects (Dean et al. , 2002 Mol Psychiatry).
- Milameline has shown efficacy versus scopolamine-induced deficits in working and spatial memory in rodents; sabcomeline displayed efficacy in a visual object discrimination task in marmosets and xanomeline reversed mAChR antagonistic ) induced deficits in cognitive performance in a passive avoidance paradigm.
- AD Alzheimer's disease
- APP membrane bound amyloid precursor protein
- APP is 0 processed by two routes, nonamyloidgenic and amyloidgenic. Cleavage of APP by v- secretase is common to both pathways, but in the former APP is cleaved by an a- secretase to yield soluble APPa. However, in the amyloidgenic route, APP is cleaved by ⁇ -secretase to yield soluble ⁇ and also ⁇ . In vitro studies have shown that mAChR agonists can promote the processing of APP toward the soluble, non- 5 amyloidogenic pathway.
- mAChR agonists display an atypical antipsychotic-like profile in a range of pre-clinical paradigms.
- the mAChR agonist, xanomeline reverses a number of dopamine mediated behaviours, including amphetamine induced locomotion in rats, apomorphine induced climbing in mice, 35 dopamine agonist driven turning in unilateral 6-OH-DA lesioned rats and amphetamine induced motor unrest in monkeys (without EPS liability). It also has been shown to inhibit A10, but not A9, dopamine cell firing and conditioned avoidance and induces c- fos expression in prefrontal cortex and nucleus accumbens, but not in striatum in rats. These data are all suggestive of an atypical antipsychotic-like profile (Mirza et al., 1999 CNS Drug Rev).
- Xanomeline, sabcomeline, milameline and cevimeline have all progressed into various stages of clinical development for the treatment of Alzheimer's disease and/or schizophrenia.
- Phase II clinical studies with xanomeline demonstrated its efficacy versus various cognitive symptom domains, including behavioural disturbances and hallucinations associated with Alzheimer's disease (Bodick et al., 1997 Arch Neurol). This compound was also assessed in a small Phase II study of schizophrenics and gave a significant reduction in positive and negative symptoms when compared to placebo control (Shekhar et al., 2008 Am J Psych).
- xanomeline and other related mAChR agonists have displayed an unacceptable safety margin with respect to cholinergic adverse events, including nausea, gastrointestinal pain, diahorrhea, diaphoresis (excessive sweating), hypersalivation (excessive salivation), syncope and bradycardia.
- Muscarinic receptors are involved in central and peripheral pain. Pain can be divided into three different types: acute, inflammatory, and neuropathic. Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage; however management of post-surgical pain is required. Inflammatory pain may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion and is triggered by the action of inflammatory mediators such as neuropeptides and prostaglandins which result in neuronal inflammation and pain. Neuropathic pain is associated with abnormal painful sensations to non-painful stimuli. Neuropathic pain is associated with a number of different diseases/traumas such as spinal cord injury, multiple sclerosis, diabetes (diabetic neuropathy), viral infection (such as HIV or Herpes).
- diseases/traumas such as spinal cord injury, multiple sclerosis, diabetes (diabetic neuropathy), viral infection (such as HIV or Herpes).
- muscarinic receptors have been shown to be analgesic across a number of pain states through the activation of receptors in the spinal cord and higher pain centres in the brain.
- Increasing endogenous levels of acetylcholine through acetylcholinesterase inhibitors direct activation of muscarinic receptors with agonists or allosteric modulators has been shown to have analgesic activity.
- blockade of muscarinic receptors with antagonists or using knockout mice increases pain sensitivity.
- Evidence for the role of the M1 receptor in pain is reviewed by D. F. Fiorino and M. Garcia-Guzman, 2012.
- the present invention provides compounds having activity as muscarinic M 1 receptor agonists. More particularly, the invention provides compounds that exhibit selectivity for the M 1 receptor relative to the M2, M3 and M4 receptor subtypes.
- the invention provides a compound of the form
- n 1 or 2;
- p 0, 1 or 2;
- q 0, 1 or 2;
- R 1 is a Ci-io non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof;
- R 2 is hydrogen or a CMO non-aromatic hydrocarbon group
- R 1 and R 2 together with the nitrogen atom to which they are attached form a non- aromatic heterocyclic group of four to nine ring members, wherein the heterocyclic ring may optionally contain a second heteroatom selected from O, N and S and oxidised forms thereof; and wherein the heterocyclic ring may optionally be substituted with one to six more subsitutents selected from Ci -2 alkyl; fluorine; and cyano;
- R 3 is selected from hydrogen; halogen; cyano; hydroxy; Ci -3 alkoxy; and a Ci -5 non- aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S;
- R 4 is a C1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof;
- R 5 is absent or is fluorine
- R 6 is absent or is fluorine.
- Figures 1-4 show the efficacy of the compounds of the invention.
- Figures 1-3 relate to the passive avoidance assay described in part B. Studies were carried out as described previously by Foley et al., (2004) Neuropsychopharmacology. In the passive avoidance task scopolamine administration (1 mg/kg, i.p.) at 6 hours following training rendered animals amnesic of the paradigm. A dose range of 3, 10, and 30 mg/kg (po) free base, administered 90 minutes prior to the training period via oral gavage, was examined.
- Figure 1 shows that Example 27 was found to reverse scopolamine-induced amnesia of the paradigm in a dose-dependent manner, with an approximate ED 50 of ca. 10 mg/kg (po). The effect of 30 mg/kg was similar to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, ip) which served as a positive control.
- Figure 2 shows that Example 65 was found to reverse scopolamine-induced amnesia of the paradigm in a dose-dependent manner, with significant effects observed after acute administration of 10 and 30 mg/kg (p ⁇ 0.05; Bonferroni post hoc test). The effect at 10 and 30 mg/kg was not significantly different to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, i.p.), which served as a positive control.
- Figure 3 shows that Example 65 was found to reverse scopolamine-induced amnesia in a dose-dependent manner, with significant effects observed after acute administration of 10 mg/kg (po) (p ⁇ 0.05; Bonferroni post hoc test).
- Example 65 The effect at 10 mg/kg was not significantly different to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, i.p.), which served as a positive control.
- Combination of Example 65 and donepezil did not result in a loss of activity, rather the combination had an additive effect at each dose combination as analysed by Mann Whitney u-test.
- Figure 4 shows the effects of Example 65 in a rodent object recognition assay described in Example D.
- Statistical analysis determined that treatment with 10 and 30 mg/kg for Example 65 and 3 mg/kg of the positive control galanthamine significantly improved novel object recognition memory when compared to vehicle-treated controls (p ⁇ 0.05).
- Donepezil 0.1 mg/kg was without effect on novel object recognition.
- animals were scored for exploratory behaviour. There was no difference as regards exploration for either object or between vehicle-treated controls and any drug treatment group.
- the present invention provides compounds having activity as muscarinic M1 receptor agonists. More particularly, the invention provides compounds that exhibit selectivity for the M1 receptor relative to the M2, M3 and M4 receptor subtypes.
- the invention provides a compound of the formu
- n 1 or 2;
- p 0, 1 or 2;
- q 0, 1 or 2;
- R 1 is a Ci-io non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof;
- R 2 is hydrogen or a CMO non-aromatic hydrocarbon group
- R 1 and R 2 together with the nitrogen atom to which they are attached form a non- aromatic heterocyclic group of four to nine ring members, wherein the heterocyclic ring may optionally contain a second heteroatom selected from O, N and S and oxidised forms thereof; and wherein the heterocyclic ring may optionally be substituted with one to six more subsitutents selected from Ci -2 alkyl; fluorine; and cyano;
- R 3 is selected from hydrogen; halogen; cyano; hydroxy; Ci -3 alkoxy; and a Ci -5 non- aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S;
- R 4 is a Ci-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof;
- R 5 is absent or is fluorine
- R 6 is absent or is fluorine.
- R 1 is a C1-10 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof; the CMO non-aromatic hydrocarbon group containing 0, 1 or 2 carbon-carbon multiple bonds.
- R 1 is selected from Ci -6 alkyl; C 2- 6 alkenyl; C 2- 6 alkynyl; and CMO non-aromatic hydrocarbon groups consisting of or containing a C 3- io cycloalkyl or C 5 - 6 cycloalkenyl group; each of the said alkyl, alkenyl, alkynyl and non-aromatic hydrocarbon groups being optionally substituted with one to six fluorine atoms; and wherein one or two, but not all, carbon atoms of each of the alkyl, alkenyl, alkynyl and non-aromatic hydrocarbon groups may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof.
- Ci-6 alkyl optionally substituted with 1 to 6 fluorine atoms
- R 1 is selected from groups A, B, D, E, F, G, L, M, N, O, Q, R, T, V, W, Y, AA, AB, AC, AJ, AK, AO, AP and
- R 1 is selected from 2-methylpropyl, te/f-butyl, 2-methylbutyl, 2,2- dimethylpropyl, 2-methylbut-2-yl, cyclobutylmethyl, cyclopropylmethyl, cyclopentylmethyl, isopropyl, 1-methylcyclohexyl, 1-methylcyclopentylmethyl, 2- cyclopropylpropyl, 1-methylcyclobutyl, cyclopentyl, 2,3-dimethylbutan-2-yl, 1- ethylcyclobutylmethyl, 1-methylcyclopentyl, 2-cyclopropylpropan-2-yl, cyclobutyl, 1- methylcyclobutylmethyl, 1-(trifluoromethyl)cyclobutyl, 1-ethylcyclobutyl,
- R 1 is selected from 2-methylpropyl; 2,2-dimethylpropyl; tert-butyl; 2-methyl-but-2-yl; 2,3- dimethylbut-2-yl; cyclopropylmethyl; cyclobutylmethyl; cyclopentyl; cyclopentylmethyl; 1-methylcyclobutyl; 1-methylcyclopentyl; 1 methylcyclohexyl; 1-methylcyclopentylmethyl; cyclopropyl-prop-2-yl; and 1-ethyl-cyclobutylmethyl groups.
- R 1 is selected from groups A, F, G, O, R, T, V, W, Y, AA, AB, AJ, AO and AP
- R' is selected from 2-methylpropyl, 2- methylbut-2-yl, cyclobutylmethyl, 1-methylcyclohexyl, 2-cyclopropylpropyl, 1- methylcyclobutyl, cyclopentyl, 2,3-dimethylbutan-2-yl, 1 -ethylcyclobutylmethyl, 1- methylcyclopentyl, 2-cyclopropylpropan-2-yl,1-methylcyclobutylmethyl and 1- ethylcyclobutyl and ( 2 H 3 )methyl( 2 H 6 )propyl groups).
- R 3 is selected from hydrogen, halogen, cyano, hydroxy, Ci -3 alkoxy and Ci_ 4 alkyl.
- R 1 , R 3 , R 4 , R 5 , R 6 , p and q are as defined in any one of Embodiments 1.1 and 1.3 to 1.39.
- R 1 , R 3 , R 4 , R 5 , R 6 , p and q are as defined in any one of Embodiments 1.1 and 1.3 to 1.39.
- R 1 , R 3 , R 4 , R 5 , R 6 , p and q are as defined in any one of Embodiments 1.1 and 1.3 to 1.39.
- a compound according to Embodiment 1.43 which is selected from the compounds of Examples 6, 7, 8, 9, 10, 1 1 , 15, 16, 17, 18, 27, 30, 31 , 37, 39, 40, 41 , 42, 43, 44, 45, 46, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 63 and 64 and salts thereof or a compound according to Embodiment 1.43a which is selected from the compounds of Examples 65, 66, 67, 73, 74, 75, 77, 78, 79, 80, 81 and 82 and salts thereof.
- a compound according to Embodiment 1.44 which is ethyl 4-(4-((2- methylpropyl)carbamoyl)piperidin-1-yl)azepane-1-carboxylate or a salt thereof.
- Embodiment 1.45 A compound according to Embodiment 1.45 which is ethyl (4S)-4-[4-((2- methylpropyl)methylcarbamoyl)piperidin-1-yl]azepane-1-carboxylate or a salt thereof.
- a compound according to Embodiment 1.45 which is ethyl (4R)-4-[4-((2- methylpropyl)methylcarbamoyl)piperidin-1-yl]azepane-1-carboxylate or a salt thereof.
- a compound according to Embodiment 1.44 which is ethyl 4-(4-((1- methylcyclobutyl)carbamoyl)piperidin-1-yl)azepane-1-carboxylate or a salt thereof.
- Embodiment 1.48 A compound according to Embodiment 1.48 which is ethyl (4S)-4-[4-[(1- methylcyclobutyl)carbamoyl]-1-piperidyl]azepane-1-carboxylate or a salt thereof.
- treatment in relation to the uses of the compounds of the formula (1), is used to describe any form of intervention where a compound is administered to a subject suffering from, or at risk of suffering from, or potentially at risk of suffering from the disease or disorder in question.
- treatment covers both preventative (prophylactic) treatment and treatment where measurable or detectable symptoms of the disease or disorder are being displayed.
- non-aromatic hydrocarbon group refers to a group consisting of carbon and hydrogen atoms and which contains no aromatic rings.
- the hydrocarbon group may be fully saturated or may contain one or more carbon-carbon double bonds or carbon-carbon triple bonds, or mixtures of double and triple bonds.
- the hydrocarbon group may be a straight chain or branched chain group or may consist of or contain a cyclic group.
- cycloalkyl as used herein, where the specified number of carbon atoms permits, includes both monocyclic cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and bicyclic and tricyclic groups.
- Bicyclic cycloalkyl groups include bridged ring systems such as bicycloheptane, bicyclooctane and adamantane.
- the salts are typically acid addition salts.
- the salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods such as methods described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002.
- such salts can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
- Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
- Examples of acid addition salts falling within Embodiment 1.51 include mono- or di-salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g.
- D-glucuronic D-glucuronic
- glutamic e.g. L-glutamic
- a-oxoglutaric glycolic, hippuric
- hydrohalic acids e.g. hydrobromic, hydrochloric, hydriodic
- isethionic lactic (e.g.
- the compounds of the formula (1 ) may contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of formula (1 ).
- the compounds of the invention may exist as mono- or di-salts depending upon the pKa of the acid from which the salt is formed.
- salt forms of the compounds of the invention are typically pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1- 19. However, salts that are not pharmaceutically acceptable may also be prepared as intermediate forms which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in the purification or separation of the compounds of the invention, also form part of the invention.
- Stereoisomers are isomeric molecules that have the same molecular formula and sequence of bonded atoms but which differ only in the three-dimensional orientations of their atoms in space.
- the stereoisomers can be, for example, geometric isomers or optical isomers.
- the isomerism is due to the different orientations of an atom or group about a double bond, as in cis and trans (Z and E) isomerism about a carbon- carbon double bond, or cis and trans isomers about an amide bond, or syn and anti isomerism about a carbon nitrogen double bond (e.g. in an oxime), or rotational isomerism about a bond where there is restricted rotation, or cis and trans isomerism about a ring such as a cycloalkane ring.
- the invention provides a geometric isomer of a compound according to any one of Embodiments 1.1 to 1.53.
- Optical Isomers
- references to the compounds include all optical isomeric forms thereof (e.g. enantiomers, epimers and diastereoisomers), either as individual optical isomers, or mixtures (e.g. racemic mixtures) or two or more optical isomers, unless the context requires otherwise. Accordingly, in another embodiment (Embodiment 1.54) the invention provides a compound according to any one of Embodiments 1.1 to 1.53 which contains a chiral centre.
- optical isomers may be characterised and identified by their optical activity (i.e. as + and - isomers, or d and / isomers) or they may be characterised in terms of their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, see Advanced Organic Chemistry by Jerry March, 4 th Edition, John Wiley & Sons, New York, 1992, pages 109-1 14, and see also Cahn, Ingold & Prelog, Angew. Chem. Int. Ed. Engl., 1966, 5, 385-415.
- Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support) and such techniques are well known to the person skilled in the art.
- optical isomers can be separated by forming diastereoisomeric salts with chiral acids such as (+)-tartaric acid, (-)-tartaric acid, acetyl leucine, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)- malic acid, and (-)-camphorsulphonic, separating the diastereoisomers by preferential crystallisation, and then dissociating the salts to give the individual enantiomer of the free base.
- chiral acids such as (+)-tartaric acid, (-)-tartaric acid, acetyl leucine, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)- malic acid, and (-)-camphorsulphonic
- one enantiomer in a pair of enantiomers may exhibit advantages over the other enantiomer, for example, in terms of biological activity. Thus, in certain circumstances, it may be desirable to use as a therapeutic agent only one of a pair of enantiomers, or only one of a plurality of diastereoisomers.
- the invention provides compositions containing a compound according to Embodiment 1.54 having one or more chiral centres, wherein at least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the compound of Embodiment 1.54 is present as a single optical isomer (e.g. enantiomer or diastereoisomer).
- Embodiment 1.54 99% or more (e.g. substantially all) of the total amount of the compound (or compound for use) of Embodiment 1.54 is present as a single optical isomer.
- the compound is present as a single enantiomer.
- the compound is present as a single diastereoisomer.
- the invention also provides mixtures of optical isomers, which may be racemic or non- racemic.
- the invention provides: 1.59 A compound according to Embodiment 1.54 which is in the form of a racemic mixture of optical isomers.
- the compounds of the invention as defined in any one of Embodiments 1.1 to 1.60 may contain one or more isotopic substitutions, and a reference to a particular element includes within its scope all isotopes of the element.
- a reference to hydrogen includes within its scope 1 H, 2 H (D), and 3 H (T).
- references to carbon and oxygen include within their scope respectively 12 C, 13 C and 1 C and 16 0 and 18 0.
- a reference to a particular functional group also includes within its scope isotopic variations, unless the context indicates otherwise.
- a reference to an alkyl group such as an ethyl group also covers variations in which one or more of the hydrogen atoms in the group is in the form of a deuterium or tritium isotope, e.g. as in an ethyl group in which all five hydrogen atoms are in the deuterium isotopic form (a perdeuteroethyl group).
- the isotopes may be radioactive or non-radioactive.
- the compound of any one of Embodiments 1.1 to 1.60 contains no radioactive isotopes. Such compounds are preferred for therapeutic use.
- the compound of any one of Embodiments 1.1 to 1.60 may contain one or more radioisotopes. Compounds containing such radioisotopes may be useful in a diagnostic context.
- solvates are solvates formed by the incorporation into the solid state structure (e.g. crystal structure) of the compounds of the invention of molecules of a non-toxic pharmaceutically acceptable solvent (referred to below as the solvating solvent).
- solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethylsulphoxide.
- Solvates can be prepared by recrystallising the compounds of the invention with a solvent or mixture of solvents containing the solvating solvent.
- Whether or not a solvate has been formed in any given instance can be determined by subjecting crystals of the compound to analysis using well known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography.
- TGE thermogravimetric analysis
- DSC differential scanning calorimetry
- X-ray crystallography X-ray crystallography.
- the solvates can be stoichiometric or non-stoichiometric solvates.
- Particularly preferred solvates are hydrates, and examples of hydrates include hemihydrates, monohydrates and di hydrates.
- the invention provides:
- the compound of the invention may be anhydrous. Therefore, in another embodiment (Embodiment 1.65), the invention provides a compound as defined in any one of Embodiments 1.1 to 1.62 in an anhydrous form (e.g. anhydrous crystalline form). Crystalline and amorphous forms
- the compounds of any one of Embodiments 1.1 to 1.65 may exist in a crystalline or non-crystalline (e.g. amorphous) state. Whether or not a compound exists in a crystalline state can readily be determined by standard techniques such as X-ray powder diffraction (XRPD). Crystals and their crystal structures can be characterised using a number of techniques including single crystal X-ray crystallography, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and infra red spectroscopy, e.g. Fourier Transform infra-red spectroscopy (FTIR).
- XRPD X-ray powder diffraction
- DSC differential scanning calorimetry
- FTIR Fourier Transform infra-red spectroscopy
- the behaviour of the crystals under conditions of varying humidity can be analysed by gravimetric vapour sorption studies and also by XRPD.
- Determination of the crystal structure of a compound can be performed by X-ray crystallography which can be carried out according to conventional methods such as those described herein and as described in Fundamentals of Crystallography, C. Giacovazzo, H. L. Monaco, D. Viterbo, F. Scordari, G. Gilli, G. Zanotti and M. Catti, (International Union of Crystallography/Oxford University Press, 1992 ISBN 0-19-855578-4 (p/b), 0-19-85579- 2 (h/b)).
- This technique involves the analysis and interpretation of the X-ray diffraction of single crystal.
- the invention provides: 1.66 A compound according to any one of Embodiments 1.1 to 1.65 in a crystalline form.
- prodrugs are meant for example any compound that is converted in vivo into a biologically active compound of the formula (1), as defined in any one of Embodiments 1.1 to 1.62.
- esters may be formed by esterification, for example, of any hydroxyl groups present in the parent compound with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.
- prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.).
- the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
- the invention provides a prodrug of a compound as defined in any one of Embodiments 1.1 to 1.62 wherein the compound contains a functional group which is convertable under physiological conditions to form a hydroxyl group or amino group.
- Embodiments 1.1 to 1.69 Also encompassed by formula (1) in Embodiments 1.1 to 1.69 are complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals) of the compounds of Embodiments 1.1 to 1.69. Accordingly, in another embodiment (Embodiment 1.70), the invention provides a compound according to any one of Embodiments 1.1 to 1.69 in the form of a complex or clathrate. Biological activity and therapeutic uses
- the compounds of the present invention have activity as muscarinic M1 receptor agonists.
- the muscarinic activity of the compounds can be determined using the Phospho-ERK1/2 assay described in Example A below.
- a significant advantage of compounds of the invention is that they have selectivity for the M1 receptor relative to the M2 and M3 receptor subtypes.
- compounds of the invention typically have pEC 50 values of at least 6 (preferably at least 6.5) and E max values of greater than 80 (preferably greater than 100) against the M1 receptor in the functional assay described in Example A, they may have pEC 50 values of less than 6 (and usually less than 5) and E max values of less than 50% when tested against the M2 and M3 subtypes in the functional assay of Example A.
- a compound according to any one of Embodiments 1.1 to 1.70 which is a muscarinic M1 receptor agonist having a pEC 50 in the range from 6.0 to 7.9 and an E max of at least 90 against the M1 receptor in the assay of Example A herein or an assay substantially similar thereto.
- a compound according to Embodiment 2.3 which is a muscarinic M1 receptor agonist having a pEC 50 in the range from 6.5 to 7.5.
- Embodiment 2.3 which is a muscarinic M1 receptor agonist having a pEC50 in the range from 6.8 to 7.9.
- Embodiment 2.3 A compound according to Embodiment 2.3 which is a muscarinic M1 receptor agonist having a pEC50 in the range from 7.1 to 7.9.
- Embodiment 2.5 A compound according to Embodiment 2.3, Embodiment 2.4, Embodiment 2.4a or Embodiment 2.4b having an E max of at least 100 against the M1 receptor.
- Embodiment 2.7 A compound according to Embodiment 2.7 which has a pEC 50 of less than 4.5 and/or an E max of less than 30 against the muscarinic M2 and M3 receptor subtypes.
- Embodiments 1.1 to 1.70 and Embodiments 2.3 to 2.8 for use in the treatment of a disease or condition mediated by the muscarinic M 1 receptor.
- compounds of the invention can be used in the treatment of Alzeimer's disease, schizophrenia and other psychotic disorders, cognitive disorders and other diseases mediated by the muscarinic M1 receptor.
- the invention provides:
- the cognitive disorder or psychotic disorder comprises, arises from or is associated with a condition selected from cognitive impairment, mild cognitive impairment, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Friederich's ataxia, Down's syndrome, Huntington's chorea, hyperkinesia, mania, Tourette's syndrome, Alzheimer's disease, progressive supranuclear palsy, impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e.
- cognitive disorders as a result of stroke, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as multiinfarct dementia, alcoholic dementia, hypothyroidism-related dementia, and dementia associated with other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders; cognitive disorders due to drug abuse or drug withdrawal including nicotine, cannabis, amphetamine, cocaine, Attention Deficit Hyperactivity Disorder (ADHD) and dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism
- ADHD Attention Deficit Hyperactivity Disorder
- a method of treatment of a cognitive disorder in a subject which method comprises the administration of a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.70.
- Embodiment 2.16 A method according to Embodiment 2.15 wherein the cognitive disorder arises from or is associated with Alzheimer's disease.
- Embodiment 2.10 wherein the cognitive disorder comprises, arises from or is associated with a condition as defined in Embodiment 2.1 1.
- Embodiment 2.19 wherein the cognitive disorder arises from or is associated with Alzheimer's disease.
- a method of treatment of peripheral disorders such as reduction of intra ocular pressure in glaucoma and treatment of dry eyes and dry mouth including Sjogren's Syndrome, which method comprises the administration of a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.70.
- the invention provides a process for the preparation of a compound as defined in any one of Embodiments 1.1 to 1.70, which process comprises:
- R 3 , R 4 , R 5 and R 6 are as defined in any one of Embodiments 1.1 to 1.70 with a compound of the formula R 1 R 2 NH under amide-forming conditions; or
- the reaction may be carried out in the presence of a reagent of the type commonly used in the formation of amide bonds.
- reagents include 1 ,3-dicyclohexylcarbodiimide (DCC) (Sheehan et al, J. Amer. Chem Soc. 1955, 77, 1067), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (referred to herein either as EDC or EDAC) (Sheehan et al, J. Org.
- uronium-based coupling agents such as 0-(7-azabenzotriazol-1-yl)-/ ⁇ /,A/,A/',A/-tetramethyluronium hexafluorophosphate (HATU) and phosphonium-based coupling agents such as 1- benzo-triazolyloxytris-(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (Castro et al, Tetrahedron Letters, 1990, 3J . , 205).
- Carbodiimide-based coupling agents are advantageously used in combination with 1-hydroxy-7-azabenzotriazole (HOAt) (L. A. Carpino, J.
- a preferred amide coupling agent is HATU.
- the coupling reaction is typically carried out in a non-aqueous, non-protic solvent such as acetonitrile, dioxane, dimethylsulphoxide, dichloromethane, dimethylformamide or N-methylpyrrolidinone, or in an aqueous solvent optionally together with one or more miscible co-solvents.
- a non-aqueous, non-protic solvent such as acetonitrile, dioxane, dimethylsulphoxide, dichloromethane, dimethylformamide or N-methylpyrrolidinone
- the reaction can be carried out at room temperature or, where the reactants are less reactive at an appropriately elevated temperature, for example a temperature up to about 100 °C, e.g. 50-80 °C.
- the reaction may optionally be carried out in the presence of a non-interfering base, for example a tertiary amine such as triethylamine or A/,A/-diisopropylethyl
- a reactive derivative of the carboxylic acid e.g. an anhydride or acid chloride
- the acid chloride is typically reacted with the compound of formula R 1 R 2 NH in the presence of a base such as sodium bicarbonate or sodium hydroxide.
- the acid chloride can be prepared using standard methods, for example by treatment of the acid with oxalyl chloride in the presence of a catalytic amount of dimethylformamide.
- Process variant (B) is typically carried out in an aprotic solvent such as dichloromethane or dichloroethane in the presence of a non-interfering base such as triethylamine.
- the reaction may be conducted at room temperature.
- reaction Scheme 1 the piperidine carboxylic acid (12) is reacted with the substituted ketone (13) under reductive amination conditions.
- the reductive amination reaction is typically carried out with mild heating (e.g. to a temperature of from about 40 °C to about 70° C) using a borohydride reducing agent such as sodium triacetoxy- borohydride in a solvent such as dichloromethane or dichloroethane containing acetic acid.
- a borohydride reducing agent such as sodium triacetoxy- borohydride
- solvent such as dichloromethane or dichloroethane containing acetic acid.
- an ester e.g.
- the starting material for the reaction sequence shown in Scheme 3 is the protected (4S)-4-aminoazepine derivative (17) in which the ring nitrogen of the azepine is protected by a Boc group and the 4-amino moiety is protected as a (1 R)-1- phenethylamino group.
- the first step of the reaction sequence involves the removal of the phenethylamine protecting group using palladium hydroxide on carbon and ammonium formate in methanol with heating to give the 4-aminoazepine (18).
- the 4- aminoazepine (18) is then reacted with the dialdehyde (20) (which can be generated in situ by subjecting methyl cyclopent-3-ene-1-carboxylate to ozonolysis) under reductive amination conditions as described above (e.g. using sodum triacetoxyborohydride) to give the piperidinyl-azepine (21).
- Hydrolysis of the piperidine carboxylic ester group using sodium hydroxide gives the (S) optical isomer of the N-protected-azepinyl- piperidinyl carboxylic acid (16).
- one compound of the formula (1 ), or a protected derivative thereof can be converted into another compound of the formula (1 ) by methods well known to the skilled person.
- Examples of synthetic procedures for converting one functional group into another functional group are set out in standard texts such as Advanced Organic Chemistry and Organic Syntheses (see references above) or Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471- 58283-2).
- the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation).
- a pharmaceutical composition e.g. formulation
- a pharmaceutical composition comprising at least one compound of the formula (1) as defined in any one of Embodiments 1.1 to 1.70 together with at least one pharmaceutically acceptable excipient.
- the composition is a tablet composition.
- the composition is a capsule composition.
- the pharmaceutically acceptable excipient(s) can be selected from, for example, carriers (e.g. a solid, liquid or semi-solid carrier), adjuvants, diluents (e.g solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and co-solvents), granulating agents, binders, flow aids, coating agents, release-controlling agents (e.g.
- binding agents disintegrants, buffering agents, lubricants, preservatives, anti-fungal and antibacterial agents, antioxidants, buffering agents, tonicity-adjusting agents, thickening agents, flavouring agents, sweeteners, pigments, plasticizers, taste masking agents, stabilisers or any other excipients conventionally used in pharmaceutical compositions.
- pharmaceutically acceptable means compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. a human subject) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each excipient must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Pharmaceutical compositions containing compounds of the formula (1) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
- compositions can be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration.
- Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches such as buccal patches.
- Tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, eg; lactose, sucrose, sorbitol or mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as microcrystalline cellulose (MCC), methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch.
- Tablets may also contain such standard ingredients as binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g.
- swellable crosslinked polymers such as crosslinked carboxymethylcellulose
- lubricating agents e.g. stearates
- preservatives e.g. parabens
- antioxidants e.g. BHT
- buffering agents for example phosphate or citrate buffers
- effervescent agents such as citrate/bicarbonate mixtures.
- Tablets may be designed to release the drug either upon contact with stomach fluids (immediate release tablets) or to release in a controlled manner (controlled release tablets) over a prolonged period of time or with a specific region of the Gl tract.
- the pharmaceutical compositions typically comprise from approximately 1 % (w/w) to approximately 95%, preferably% (w/w) active ingredient and from 99% (w/w) to 5% (w/w) of a pharmaceutically acceptable excipient (for example as defined above) or combination of such excipients.
- a pharmaceutically acceptable excipient for example as defined above
- the compositions comprise from approximately 20% (w/w) to approximately 90% (w/w) active ingredient and from 80% (w/w) to 10% of a pharmaceutically excipient or combination of excipients.
- the pharmaceutical compositions comprise from approximately 1 % to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
- compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, pre-filled syringes, dragees, powders, tablets or capsules.
- Tablets and capsules may contain, for example, 0-20% disintegrants, 0-5% lubricants, 0-5% flow aids and/or 0-99% (w/w) fillers/ or bulking agents (depending on drug dose). They may also contain 0-10% (w/w) polymer binders, 0-5% (w/w) antioxidants, 0-5% (w/w) pigments.
- Slow release tablets would in addition typically contain 0-99% (w/w) release-controlling (e.g. delaying) polymers (depending on dose).
- the film coats of the tablet or capsule typically contain 0-10% (w/w) polymers, 0-3% (w/w) pigments, and/or 0-2% (w/w) plasticizers.
- Parenteral formulations typically contain 0-20% (w/w) buffers, 0-50% (w/w) cosolvents, and/or 0-99% (w/w) Water for Injection (WFI) (depending on dose and if freeze dried).
- WFI Water for Injection
- Formulations for intramuscular depots may also contain 0-99% (w/w) oils.
- the pharmaceutical formulations may be presented to a patient in "patient packs" containing an entire course of treatment in a single package, usually a blister pack.
- the compounds of the formula (1) will generally be presented in unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity.
- a formulation may contain from 1 nanogram to 2 grams of active ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).
- a unit dosage form may contain from 1 milligram to 2 grams, more typically 10 milligrams to 1 gram, for example 50 milligrams to 1 gram, e.g. 100 miligrams to 1 gram, of active compound.
- the active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect (effective amount).
- a patient in need thereof for example a human or animal patient
- an amount sufficient to achieve the desired therapeutic effect (effective amount).
- the precise amounts of compound administered may be determined by a supervising physician in accordance with standard procedures.
- TLC for monitoring reactions refers to TLC run using the specified mobile phase and the silica gel F254 as a stationary phase from Merck. Microwave-mediated reactions were performed in Biotage Initiator or CEM Discover microwave reactors.
- Mass spectroscopy was carried out on Shimadzu LC-2010 EV, Waters ZQ-2000, UPLC-Mass SQD-3100 or Applied Biosystem API-2000 spectrometers using electrospray conditions as specified for each compound in the detailed experimental section.
- Preparative HPLC was typically carried out under the following conditions, (Waters HPLC): Column: XSelect CSH Prep C-18, 19 x 50 mm, 5 ⁇ ; Mobile phase: Gradients of water and MeCN (each containing 0.1 % Formic Acid); gradient 5% MeCN in 0.1 HCOOH in water (30 sec), 5% to 40% (over 7 min) then 95% MeCN in 0.1 HCOOH in water (1 min) then 5% MeCN in 0.1 HCOOH in water (1.5 min) at 28 mL / min.
- Waters HPLC Column: XSelect CSH Prep C-18, 19 x 50 mm, 5 ⁇ ; Mobile phase: Gradients of water and MeCN (each containing 0.1 % Formic Acid); gradient 5% MeCN in 0.1 HCOOH in water (30 sec), 5% to 40% (over 7 min) then 95% MeCN in 0.1 HCOOH in water (1 min) then 5% MeCN in 0.1 HCOOH in water (1.5 min) at 28 m
- HATU 2-(7-Aza-1 H-benzotriazole-1-yl)-1 ,1 ,3,3-tetramethyluronium
- n-, s-, / ' -, t- and tert- have their usual meanings: normal, secondary, / ' so, and tertiary.
- Ethyl isonipecotate (2.54 g, 2.50 ml_, 16.2 mmol) and 4-oxoazepane-1-carboxylic acid ethyl ester (3.00 g, 16.2 mmol) were dissolved in DCM (100 ml_) at rt and titanium isopropoxide (5.07 g, 5.40 ml_, 17.8 mmol) was added.
- the reaction mixture was stirred at rt for 1 h.
- STAB (13.7 g, 32.4 mmol) and acetic acid (0.5 ml_) were added and the reaction mixture was stirred at rt overnight under nitrogen.
- the reaction mixture was quenched with the addition of water (5 ml.) and stirred for 5 minutes.
- the reaction mixture was diluted with DCM and filtered through a pad of celite. The filtrate was washed with sat. NaHC0 3 sol., sat. NaCI sol. and dried over MgS0 4 . The solvents were removed in vacuo, and the residue was purified by column chromatography (normal phase, [Biotage SNAP cartridge KP-sil 50 g, 40-63 ⁇ , 60 A, 50 ml_ per min, gradient 2% to 4% MeOH in DCM]) to give ethyl 4-[4-(ethoxycarbonyl)piperidin-1- yl]azepane-1-carboxylate (2.56 g, 48%) as a pale yellow oil.
- column chromatography normal phase, [Biotage SNAP cartridge KP-sil 50 g, 40-63 ⁇ , 60 A, 50 ml_ per min, gradient 2% to 4% MeOH in DCM]
- Ethyl 4-fluoropiperidine-4-carboxylate hydrochloride (3.00 g, 14.2 mmol) was dissolved in methanol (20 mL) and treated with K 2 C0 3 (1.95 g, 14.2 mmol) in a minimum of water to de-salt. Reaction mixture was concentrated in vacuo and azeotroped to dryness with toluene. The residue and 4-oxoazepane-1-carboxylic acid ethyl ester (2.62 g, 14.2 mmol) were dissolved in methanol (50 mL) and zinc chloride (7.23 g, 56.7 mmol) was added.
- reaction mixture was stirred at 50°C, under a nitrogen atmosphere, for 2 h then cooled to rt.
- NaCNBH 4 (1.78 g, 28.4 mmol) was added and the reaction mixture was stirred at 50°C overnight under nitrogen.
- the reaction mixture was cooled to rt and the solvents were removed in vacuo, the residue was diluted with DCM and treated with sat. NaHC0 3 sol., the resulting heterogeneous mixture was filtered through a celite pad and the filtrate was washed with sat. NaHC0 3 sol., sat. NaCI sol. and dried over MgS0 4 .
- Ethyl-4-methylpiperidine-4-carboxylate hydrochloride (0.50 g, 2.42 mmol) was dissolved in methanol (10 mL) and treated with K 2 C0 3 (0.33 g, 2.42 mmol) in a minimum of water to de-salt. Reaction mixture was concentrated in vacuo and azeotroped to dryness with toluene. The residue and 4-oxoazepane-1-carboxylic acid ethyl ester (0.45 g, 2.42 mmol) were dissolved in DCM (20 mL) at rt and titanium isopropoxide (0.76 g, 0.8 mL, 2.66 mmol) was added.
- reaction mixture was stirred at rt for 5h.
- STAB (2.05 g, 9.66 mmol) and acetic acid (0.3 mL) were added and the reaction mixture was stirred at rt overnight under nitrogen.
- the reaction mixture was quenched with the addition of water (5 mL) and stirred for 5 minutes.
- the reaction mixture was diluted with DCM and filtered through a pad of celite. The filtrate was washed with sat. NaHC0 3 sol., sat. NaCI sol. and dried over MgS0 4 .
- Ethyl isonipecotate (2.28 g, 2.25 ml_, 14.5 mmol) and 4-oxoazepane-1-carboxylic acid te/f-butyl ester (3.00 g, 14.5 mmol) were dissolved in DCM (60 ml_) at rt and titanium isopropoxide (4.12 g, 4.40 ml_, 14.5 mmol) was added. The reaction mixture was stirred at rt for 1 h. STAB (13.74 g, 32.4 mmol) and acetic acid (0.5 ml_) were added and the reaction mixture was stirred at rt overnight under nitrogen.
- reaction mixture was quenched with the addition of water (5 ml_) and stirred for 5 minutes.
- the reaction mixture was diluted with DCM and filtered through a pad of celite. The filtrate was washed with sat. NaHC0 3 sol., sat. NaCI sol. and dried over MgS0 4 .
- Residue was dissolved in DMF (30 ml_) and isobutylamine (0.81 g, 1.1 ml_, 11.0 mmol), HATU (4.20 g, 1 1.0 mmol) and DIPEA (4.76 g, 6.41 ml_, 36.8 mmol) were added.
- the reaction mixture was stirred at rt for 48 h under nitrogen.
- the solvents were removed in vacuo, and the residue was partitioned between DCM and sat. NaHC0 3 sol., organic layer washed with sat. NaCI sol. and dried over MgS0 4 .
- the reaction mixture was stirred at 50°C for 3h.
- the solution was cooled to room temperature, sodium cyanoborohydride (0.299 g, 4.77 mmol) was added and the reaction mixture was stirred at 50°C overnight under nitrogen.
- the solvents were removed in vacuo, and the residue was partitioned between DCM and sat. NaHC0 3 sol.
- the aqueous phase was extracted with DCM (2 x 20 mL). The organics were combined, washed with sat. NaCI sol. and dried by passing through a Biotage Phase Separator cartridge.
- reaction mixture was quenched with the addition of water and the solvents were removed in vacuo.
- the residue was partitioned between DCM and sat. NaHC0 3 sol.
- the organic layer was washed with sat. NaCI sol. and dried by passing through a Biotage Phase Separator cartridge.
- reaction mixture was stirred at rt overnight and then partitioned between DCM and sat.NaHC0 3 sol.
- the organic layer was washed with sat. NaCI sol. and dried (MgS0 4 ) and the solvent was removed in vacuo.
- the residue was purified by trituration from diethyl ether to give ethyl 4-(2-methylpropyl)carbamoyl)-1 ,4'- bipiperidine-1 '-carboxylate (0.01 g, 9%) as a white solid.
- Example 63 te/f-butyl (4S)-4-[4-(methoxycarbonyl)piperidin-1-yl]azepane-1 -carboxylate (0.3 g, 0.92 mmol) was dissolved in DMF (4 mL) and isobutylamine (0.14 g, 0.18 mL, 1.84 mmol), HATU (0.53 g, 1.38 mmol) and DIPEA (0.36 g, 0.48 mL, 2.76 mmol) were added. The reaction mixture was stirred at rt for 48 h and the solvents were removed in vacuo. The residue was partitioned between DCM and sat. NaHC0 3 sol., the organic layer was washed with sat.
- Residue was dissolved in DCM (4 mL) and TFA (1 mL) was added. The reaction mixture was stirred at rt for 2h under nitrogen, then the solvents were removed in vacuo. The residue was dissolved in DCM (8 mL) at rt. NEt 3 (0.13 mL, 0.96 mmol) and ethyl chloroformate (0.05 mL, 0.48 mmol) were added and the reaction mixture was stirred at rt overnight under nitrogen. The solvents were removed in vacuo, and the residue was partitioned between DCM and sat. NaHC0 3 sol.), organic layer washed with sat. NaCI sol. and dried over MgS0 4 .
- ERK1/2 phosphorylation is a downstream consequence of both Gq/11 and Gi/o protein coupled receptor activation, making it highly suitable for the assessment of Ml, M3 (Gq/11 coupled) and M2, M4 receptors (Gi/o coupled), rather than using different assay formats for different receptor subtypes.
- CHO cells stably expressing the human muscarinic Ml, M2, M3 or M4 receptor were plated (25K / well) onto 96-well tissue culture plates in MEM-alpha + 10% dialysed FBS. Once adhered, cells were serum- starved overnight.
- Agonist stimulation was performed by the addition of 5 ⁇ . agonist to the cells for 5 min (37 °C). Media was removed and 50 ⁇ . of lysis buffer added. After 15 min, a 4 ⁇ . sample was transferred to 384-well plate and 7 ⁇ . of detection mixture added. Plates were incubated for 2 h with gentle agitation in the dark and then read on a PHERAstar plate reader.
- Example 27 was found to reverse scopolamine-induced amnesia of the paradigm in a dose-dependent manner, with an approximate ED 50 of ca. 10 mg/kg (po). The effect of 30 mg/kg was similar to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, ip) which served as a positive control ( Figure 1).
- Example 65 was found to reverse scopolamine-induced amnesia of the paradigm in a dose-dependent manner, with significant effects observed after acute administration of 10 and 30 mg/kg (p ⁇ 0.05; Bonferroni post hoc test). The effect at 10 and 30 mg/kg was not significantly different to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, i.p.), which served as a positive control ( Figure 2).
- Example 65 was found to reverse scopolamine-induced amnesia in a dose-dependent manner, with significant effects observed after acute administration of 10 mg/kg (po) (p ⁇ 0.05; Bonferroni post hoc test). The effect at 10 mg/kg was not significantly different to that produced by the cholinesterase inhibitor donepezil (0.1 mg/kg, i.p.), which served as a positive control. Combination of Example 65 and donepezil did not result in a loss of activity, rather the combination had an additive effect at each dose combination as analysed by Mann Whitney u-test ( Figure 3).
- the method which detects the principal effects of a test substance on behaviour and physiological function, follows that described by Irwin (1968) Psychopharmacologia. Cholinergic side effects are potentially visible in the behavioural readout of the Irwin assay, and an absence of these side effects can be taken as an indication that agonism of the M2 and M3 receptors is not significant in vivo.
- Rats are administered the test substance or its vehicle, and are observed in simultaneous comparison with a control group. Behavioural modifications, physiological and neurotoxicity symptoms, rectal temperature and pupil diameter are recorded according to a standardized observation grid derived from that of Irwin.
- the grid contains the following items: death, convulsions, tremor, Straub tail, altered activity, jumping, abnormal gait (rolling, tiptoe), motor incoordination, altered abdominal muscle tone, loss of grasping, akinesia, catalepsy, loss of traction, loss of balance, fore-paw treading, writhing, piloerection, stereotypies (sniffing, chewing, head movements), head- twitches, scratching, altered respiration, aggression, altered fear/startle, altered reactivity to touch, ptosis, exophthalmia, loss of righting reflex, loss of corneal reflex, analgesia, defecation/diarrhea, salivation, lacrimation, rectal temperature (
- Example 65 Observations were performed 15, 30, 60, 120, and 180 minutes post administration of Example 65. No significant effects on any parameter were observed at these time points at doses of 5, 10, 20 and 40 mg/kg when compared to vehicle control.
- Novel object recognition The novel object recognition paradigm is based on the greater spontaneous exploration of a novel object, compared with a familiar object, shown by rodents (Ennaceur and Delacour, 1988).
- the paradigm is considered a model of working memory and does not involve primary reinforcement such as food reward or noxious stimulus, thus making it analogous to memory tests employed in human clinical trials.
- Male Wistar rats were assessed for cognitive ability in a test apparatus comprising an open-field arena placed in a sound-attenuated room under dimmed lighting. Images of the open-field were captured by digital camera, and viewed on a monitor in an adjoining room. Each rat was subjected to the procedure separately and care taken to remove any olfactory/taste cues by cleaning the arena and test objects with alcohol between trials and rats.
- Rat hippocampal slices of 400 ⁇ thickness were cut in chilled ( ⁇ 4°C) artificial cerebrospinal fluid (aCSF, composition in mM: NaCl 127, KC1 1.6, KH 2 P0 4 1.24, MgS0 4 1.3, CaCl 2 2.4, NaHC0 3 26 and D-glucose 10) using vibratome.
- Slices were maintained in oxygenated (95% 0 2 / 5% C0 2 ) aCSF at room temperature for at least 1 hr prior to electrophysiological recording, after which they were transferred to an interface chamber and constantly perfused with warmed (30°C) oxygenated aCSF at a flow rate of 1.5-3 ml.min-1.
- fEPSPs field excitatory post synaptic potentials
- a tablet composition containing a compound of the formula (1) is prepared by mixing 50 mg of the compound with 197 mg of lactose (BP) as diluent, and 3 mg magnesium stearate as a lubricant and compressing to form a tablet in known manner.
- BP lactose
- a capsule formulation is prepared by mixing 100 mg of a compound of the formula (1) with 100 mg lactose and optionally 1 % by weight of magnesium stearate and filling the resulting mixture into standard opaque hard gelatin capsules.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK12794751.3T DK2780015T3 (en) | 2011-11-18 | 2012-11-16 | M1 MUSCARINRECEPTORAGONISTER |
CA2856076A CA2856076C (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
SG11201402405QA SG11201402405QA (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
JP2014541757A JP6083818B2 (en) | 2011-11-18 | 2012-11-16 | Muscarinic M1 receptor agonist |
EP12794751.3A EP2780015B1 (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
AU2012338581A AU2012338581B2 (en) | 2011-11-18 | 2012-11-16 | Muscarinic M1 receptor agonists |
ES12794751.3T ES2619829T3 (en) | 2011-11-18 | 2012-11-16 | M1 muscarinic receptor agonists |
IN1075KON2014 IN2014KN01075A (en) | 2011-11-18 | 2012-11-16 | |
US14/358,984 US9187451B2 (en) | 2011-11-18 | 2012-11-16 | Muscarinic M1 receptor agonists |
BR112014012056-0A BR112014012056B1 (en) | 2011-11-18 | 2012-11-16 | MUSCARINE M1 RECEPTOR AGONIST COMPOUNDS, A PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS AND USE THEREOF TO TREAT A COGNITIVE OR PSYCHOTIC DISORDER OR TO TREAT OR REDUCE THE SEVERITY OF ACUTE, CHRONIC, NEUROPATHIC OR INFLAMMATORY PAIN |
GB1410398.0A GB2511685A (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
CN201280066372.3A CN104039321B (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
HK15102310.2A HK1201737A1 (en) | 2011-11-18 | 2015-03-06 | Muscarinic m1 receptor agonists |
US14/941,328 US9573929B2 (en) | 2011-11-18 | 2015-11-13 | Muscarinic M1 receptor agonists |
US15/436,224 US9907805B2 (en) | 2011-11-18 | 2017-02-17 | Muscarinic M1 receptor agonists |
AU2017201505A AU2017201505B2 (en) | 2011-11-18 | 2017-03-06 | Muscarinic M1 receptor agonists |
US15/886,249 US10413553B2 (en) | 2011-11-18 | 2018-02-01 | Muscarinic M1 receptor agonists |
AU2018236871A AU2018236871B2 (en) | 2011-11-18 | 2018-09-28 | Muscarinic M1 receptor agonists |
US16/560,529 US10973832B2 (en) | 2011-11-18 | 2019-09-04 | Muscarinic M1 receptor agonists |
US17/226,523 US11793817B2 (en) | 2011-11-18 | 2021-04-09 | Muscarinic M1 receptor agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161632813P | 2011-11-18 | 2011-11-18 | |
US61/632,813 | 2011-11-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/358,984 A-371-Of-International US9187451B2 (en) | 2011-11-18 | 2012-11-16 | Muscarinic M1 receptor agonists |
US14/941,328 Continuation US9573929B2 (en) | 2011-11-18 | 2015-11-13 | Muscarinic M1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013072705A1 true WO2013072705A1 (en) | 2013-05-23 |
Family
ID=47278335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2012/052857 WO2013072705A1 (en) | 2011-11-18 | 2012-11-16 | Muscarinic m1 receptor agonists |
Country Status (17)
Country | Link |
---|---|
US (6) | US9187451B2 (en) |
EP (1) | EP2780015B1 (en) |
JP (2) | JP6083818B2 (en) |
CN (2) | CN106831541B (en) |
AU (3) | AU2012338581B2 (en) |
BR (1) | BR112014012056B1 (en) |
CA (1) | CA2856076C (en) |
DK (1) | DK2780015T3 (en) |
ES (1) | ES2619829T3 (en) |
GB (1) | GB2511685A (en) |
HK (1) | HK1201737A1 (en) |
HU (1) | HUE033114T2 (en) |
IN (1) | IN2014KN01075A (en) |
PL (1) | PL2780015T3 (en) |
PT (1) | PT2780015T (en) |
SG (1) | SG11201402405QA (en) |
WO (1) | WO2013072705A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
WO2015118342A1 (en) * | 2014-02-06 | 2015-08-13 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
WO2016147011A1 (en) * | 2015-03-19 | 2016-09-22 | Heptares Therapeutics Limited | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor |
WO2017021728A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limted | Muscarinic agonists |
WO2017021729A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limited | Muscarinic agonists |
WO2017021730A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limited | Muscarinic agonists |
WO2017077292A1 (en) * | 2015-11-02 | 2017-05-11 | Heptares Therapeutics Limited | Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor |
US10413553B2 (en) | 2011-11-18 | 2019-09-17 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
US11773090B2 (en) | 2018-06-22 | 2023-10-03 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US11834407B2 (en) | 2016-10-14 | 2023-12-05 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
RU2811601C1 (en) * | 2014-02-06 | 2024-01-15 | Хептарес Терапьютикс Лимитед | Bicyclic nitrogen-containing compounds as agonists of m1 muscarinic receptors |
US11945801B2 (en) | 2018-12-07 | 2024-04-02 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists |
US11999745B2 (en) | 2020-12-18 | 2024-06-04 | Heptares Therapeutics Limited | Pharmaceutical compounds |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
CN108226319A (en) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | A kind of method for detecting optical isomer in Rivastigmine patch |
JP6691928B2 (en) * | 2018-02-07 | 2020-05-13 | 株式会社ジンズホールディングス | Eyewear set and signal processing unit |
CN113121495A (en) * | 2020-01-10 | 2021-07-16 | 深圳市九明药业有限公司 | Preparation method of desloratadine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032479A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
EP1647553A1 (en) * | 2003-07-17 | 2006-04-19 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
WO2007076070A2 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2009034380A1 (en) * | 2007-09-11 | 2009-03-19 | Astrazeneca Ab | Piperidine derivatives as agonists of muscarinic receptors |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56110674A (en) | 1980-01-24 | 1981-09-01 | Janssen Pharmaceutica Nv | Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative |
US4369184A (en) | 1980-01-24 | 1983-01-18 | Janssen Pharmaceutica N.V. | 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives |
US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
GB9300194D0 (en) | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5446051A (en) | 1994-05-31 | 1995-08-29 | Eli Lilly And Company | Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists |
JP2002515008A (en) | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | Muscarinic antagonist |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
AU7478496A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
IL128050A0 (en) | 1996-08-26 | 1999-11-30 | Pfizer | Spirocyclic dopamine receptor subtype ligands |
EP0998285A4 (en) | 1997-06-18 | 2003-01-08 | Merck & Co Inc | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
GB9715892D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
WO1999032486A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
CZ286152B6 (en) | 1998-03-13 | 2000-01-12 | Miroslav Ing. Csc. Vlček | Transparent and semitransparent diffraction elements, particularly holograms and process of their production |
PT1076055E (en) * | 1998-04-28 | 2005-02-28 | Dainippon Pharmaceutical Co | 1 - [(1-SUBSTITUTED-4-PIPERIDINYL) -METHYL] -4-PIPERIDINE DERIVATIVES, PROCESS FOR PREPARING THEM, MEDICINAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES OF THESE COMPOUNDS |
AU776541B2 (en) | 1999-05-04 | 2004-09-16 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
AU780983B2 (en) | 1999-05-04 | 2005-04-28 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
CZ2002844A3 (en) | 1999-09-13 | 2002-06-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Spiroheterocyclic compounds, process of their preparation and use |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
CA2387535A1 (en) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
AU2001297648A1 (en) * | 2000-11-28 | 2002-08-28 | Eli Lilly And Company | Substituted carboxamides as inhibitors of factor xa |
CA2444595A1 (en) | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
US7067507B2 (en) | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
GB0128378D0 (en) | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
BR0215430A (en) | 2001-12-28 | 2004-12-14 | Acadia Pharm Inc | Compound and its uses, composition, method of treatment, method of increasing cholinergic receptor activity, method of treatment and prevention or reduction of symptoms associated with dysfunction in mammals |
US20040171614A1 (en) | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
EP1489078B1 (en) * | 2002-03-28 | 2010-01-06 | Mitsubishi Tanabe Pharma Corporation | Benzofuran derivative |
AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
ATE396969T1 (en) | 2002-07-31 | 2008-06-15 | Ranbaxy Lab Ltd | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)HEXANE DERIVATIVES THAT ARE SUITABLE AS MUSCARINE RECEPTOR ANTAGONISTS |
MXPA05003344A (en) | 2002-09-30 | 2005-11-23 | Neurosearch As | Novel 1,4-diazabicycloalkane derivatives, their preparation and use. |
BR0315688A (en) | 2002-11-22 | 2005-09-06 | Japan Tobacco Inc | Compounds, pharmaceutical compositions and their uses in the treatment or prevention of diseases or conditions of metabolic cell proliferation |
RU2355679C2 (en) | 2002-11-27 | 2009-05-20 | Инсайт Корпорейшн | 3-aminopyrrolidine derivatives as chemokine receptor modulators |
WO2004069828A1 (en) | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | Piperidine compound and medicinal use thereof |
EP1679069A4 (en) | 2003-10-21 | 2009-05-13 | Dainippon Sumitomo Pharma Co | Novel piperidine derivative |
ATE428422T1 (en) | 2004-02-05 | 2009-05-15 | Schering Corp | PIPERIDINE DERIVATIVES AS CCR3 ANTAGONISTS |
RU2006132465A (en) | 2004-02-10 | 2008-03-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | CCR5 CHEMOKIN RECEPTOR MODULATORS |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
WO2006058294A2 (en) | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
JP4774995B2 (en) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient |
WO2006105035A2 (en) | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
EP1900732A4 (en) | 2005-06-24 | 2009-11-18 | Toyama Chemical Co Ltd | Novel nitrogenated heterocyclic compound and salt thereof |
TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
KR20080098070A (en) | 2006-02-22 | 2008-11-06 | 버텍스 파마슈티칼스 인코포레이티드 | Spiro condensed piperidines as modulators of muscarinic receptors |
AU2007221214A1 (en) | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
EP2051712A2 (en) | 2006-08-15 | 2009-04-29 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
EP2124913A1 (en) | 2006-12-22 | 2009-12-02 | Novartis AG | 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors |
WO2008117229A1 (en) | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US20090221567A1 (en) * | 2008-02-28 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177 |
EP2274301B1 (en) | 2008-03-27 | 2012-09-26 | Janssen Pharmaceutica, N.V. | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
JP2012506883A (en) | 2008-10-29 | 2012-03-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Substituted spiroamine |
CA2747677C (en) * | 2008-12-19 | 2017-05-09 | Boehringer Ingelheim International Gmbh | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
NZ595432A (en) | 2009-04-17 | 2013-12-20 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
FR2945531A1 (en) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2011112825A2 (en) | 2010-03-10 | 2011-09-15 | Vanderbilt University | Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same |
US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
WO2011137012A1 (en) | 2010-04-27 | 2011-11-03 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US20130064770A1 (en) | 2010-05-28 | 2013-03-14 | Ge Healthcare Limited | Radiolabeled compounds and methods thereof |
BR112013006344A2 (en) | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | piperdinyl substituted lactams as gpr119 modulators, pharmaceutical composition comprising them, use and process for preparing same |
WO2012125661A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists |
JP2013010719A (en) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | Benzimidazolone and oxindole derivative, and pharmaceutical application of them |
SG11201402405QA (en) * | 2011-11-18 | 2014-09-26 | Heptares Therapeutics Ltd | Muscarinic m1 receptor agonists |
US9266857B2 (en) | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
KR102352388B1 (en) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
PT3265459T (en) | 2015-02-13 | 2019-07-17 | Suven Life Sciences Ltd | Amide compounds as 5-ht4 receptor agonists |
GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
US10259787B2 (en) | 2016-10-14 | 2019-04-16 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201709652D0 (en) | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
TW201922758A (en) | 2017-10-24 | 2019-06-16 | 美商歐樂根公司 | Enamines and diastereo-selective reduction of enamines |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202103211D0 (en) | 2021-03-08 | 2021-04-21 | Heptares Therapeutics Ltd | Pharmaceutical compounds for use in therapy |
-
2012
- 2012-11-16 SG SG11201402405QA patent/SG11201402405QA/en unknown
- 2012-11-16 DK DK12794751.3T patent/DK2780015T3/en active
- 2012-11-16 JP JP2014541757A patent/JP6083818B2/en active Active
- 2012-11-16 CN CN201710078042.0A patent/CN106831541B/en active Active
- 2012-11-16 EP EP12794751.3A patent/EP2780015B1/en active Active
- 2012-11-16 HU HUE12794751A patent/HUE033114T2/en unknown
- 2012-11-16 AU AU2012338581A patent/AU2012338581B2/en active Active
- 2012-11-16 CA CA2856076A patent/CA2856076C/en active Active
- 2012-11-16 ES ES12794751.3T patent/ES2619829T3/en active Active
- 2012-11-16 GB GB1410398.0A patent/GB2511685A/en not_active Withdrawn
- 2012-11-16 PT PT127947513T patent/PT2780015T/en unknown
- 2012-11-16 CN CN201280066372.3A patent/CN104039321B/en active Active
- 2012-11-16 BR BR112014012056-0A patent/BR112014012056B1/en active IP Right Grant
- 2012-11-16 IN IN1075KON2014 patent/IN2014KN01075A/en unknown
- 2012-11-16 PL PL12794751T patent/PL2780015T3/en unknown
- 2012-11-16 US US14/358,984 patent/US9187451B2/en active Active
- 2012-11-16 WO PCT/GB2012/052857 patent/WO2013072705A1/en active Application Filing
-
2015
- 2015-03-06 HK HK15102310.2A patent/HK1201737A1/en unknown
- 2015-11-13 US US14/941,328 patent/US9573929B2/en active Active
-
2017
- 2017-01-19 JP JP2017007283A patent/JP6404374B2/en active Active
- 2017-02-17 US US15/436,224 patent/US9907805B2/en active Active
- 2017-03-06 AU AU2017201505A patent/AU2017201505B2/en active Active
-
2018
- 2018-02-01 US US15/886,249 patent/US10413553B2/en active Active
- 2018-09-28 AU AU2018236871A patent/AU2018236871B2/en active Active
-
2019
- 2019-09-04 US US16/560,529 patent/US10973832B2/en active Active
-
2021
- 2021-04-09 US US17/226,523 patent/US11793817B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032479A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists |
EP1647553A1 (en) * | 2003-07-17 | 2006-04-19 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
WO2007076070A2 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2009034380A1 (en) * | 2007-09-11 | 2009-03-19 | Astrazeneca Ab | Piperidine derivatives as agonists of muscarinic receptors |
Non-Patent Citations (25)
Title |
---|
"Fiesers' Reagents for Organic Synthesis", vol. 1-17, JOHN WILEY |
"Pharmaceutical Salts: Properties, Selection, and Use", August 2002, pages: 388 |
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY |
A. ALKER ET AL., BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 4521 - 4525 |
BERGE ET AL.: "Pharmaceutically Acceptable Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
BODICK ET AL., ARCH NEURON, 1997 |
BRIDGES ET AL., BIOORG MED CHEM LETT, 2008 |
BRYN ET AL.: "Solid-State Chemistry of Drugs", 1999, SSCI, INC OF WEST LAFAYETTE |
BUDZIK, ACS MED CHEM LETT, 2010 |
C. GIACOVAZZO; H. L. MONACO; D. VITERBO; F. SCORDARI; G. GILLI; G. ZANOTTI; M. CATTI: "Fundamentals of Crystallography", 1992, INTERNATIONAL UNION OF CRYSTALLOGRAPHY/OXFORD UNIVERSITY PRESS |
CAHN, INGOLD; PRELOG: "Advanced Organic Chemistry", 1992, JOHN WILEY & SONS, pages: 109 - 114 |
CAHN; INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415 |
CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205 |
DEAN ET AL., MOL PSYCHIATRY, 2002 |
HANCOCK ET AL., J. PHARM. SCI, vol. 86, 1997, pages 1 |
JOHNSON ET AL., BIOORG MED CHEM LETT, 2010 |
KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034 |
L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397 |
LANGMEAD ET AL., BR J PHARMACOL, 2008 |
MIRZA ET AL., CNS DRUG REV, 1999 |
SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067 |
SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525 |
SHEKHAR ET AL., AM J PSYCH, 2008 |
T. GREENE; P. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS |
WHITEHOUSE ET AL., SCIENCE, 1982 |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11793817B2 (en) | 2011-11-18 | 2023-10-24 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US10973832B2 (en) | 2011-11-18 | 2021-04-13 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US10413553B2 (en) | 2011-11-18 | 2019-09-17 | Heptares Therapeutics Limited | Muscarinic M1 receptor agonists |
US9669013B2 (en) | 2012-09-18 | 2017-06-06 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
US9266857B2 (en) | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
US10259802B2 (en) | 2012-09-18 | 2019-04-16 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor antagonists |
AU2017204256B2 (en) * | 2012-09-18 | 2018-10-18 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
US9975890B2 (en) | 2012-09-18 | 2018-05-22 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor antagonists |
AU2013319989C1 (en) * | 2012-09-18 | 2017-08-17 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
AU2013319989B2 (en) * | 2012-09-18 | 2017-03-30 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
CN109851610A (en) * | 2014-02-06 | 2019-06-07 | 赫普泰雅治疗有限公司 | Azabicyclo compound as muscarine M1 and/or M4 receptor stimulating agent |
US9670183B2 (en) | 2014-02-06 | 2017-06-06 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists |
RU2811601C9 (en) * | 2014-02-06 | 2024-03-26 | Хептарес Терапьютикс Лимитед | Bicyclic nitrogen-containing compounds as agonists of m1 muscarinic receptors |
CN106458986A (en) * | 2014-02-06 | 2017-02-22 | 赫普泰雅治疗有限公司 | Bicyclic aza compounds as muscarinic m1 receptor and/or M4 receptor agonists |
US9926297B2 (en) | 2014-02-06 | 2018-03-27 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists |
JP2017505323A (en) * | 2014-02-06 | 2017-02-16 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
RU2811601C1 (en) * | 2014-02-06 | 2024-01-15 | Хептарес Терапьютикс Лимитед | Bicyclic nitrogen-containing compounds as agonists of m1 muscarinic receptors |
EP3406609A1 (en) * | 2014-02-06 | 2018-11-28 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic receptor agonists |
AU2015213900B2 (en) * | 2014-02-06 | 2018-12-13 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
WO2015118342A1 (en) * | 2014-02-06 | 2015-08-13 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
KR102352388B1 (en) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
CN106458986B (en) * | 2014-02-06 | 2019-01-04 | 赫普泰雅治疗有限公司 | Azabicyclo compound as muscarine M1 and/or M4 receptor stimulating agent |
US10196380B2 (en) | 2014-02-06 | 2019-02-05 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
CN109851610B (en) * | 2014-02-06 | 2021-09-21 | 赫普泰雅治疗有限公司 | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists |
RU2685230C2 (en) * | 2014-02-06 | 2019-04-17 | Хептарес Терапьютикс Лимитед | Bicyclic nitrogen-containing compounds as muscarinic m1 receptor agonists |
JP2019077725A (en) * | 2014-02-06 | 2019-05-23 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor agonists |
US10961225B2 (en) | 2014-02-06 | 2021-03-30 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor |
JP2021006571A (en) * | 2014-02-06 | 2021-01-21 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | Bicyclic aza compound as muscarinic m1 receptor agonist |
US10385039B2 (en) | 2014-02-06 | 2019-08-20 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists |
KR20160129014A (en) * | 2014-02-06 | 2016-11-08 | 헵테얼즈 테라퓨틱스 리미티드 | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
AU2019201579B2 (en) * | 2014-02-06 | 2020-08-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
US10689368B2 (en) | 2014-02-06 | 2020-06-23 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor |
AU2016231951B9 (en) * | 2015-03-19 | 2020-04-16 | Heptares Therapeutics Limited | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor |
WO2016147011A1 (en) * | 2015-03-19 | 2016-09-22 | Heptares Therapeutics Limited | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor |
US10167284B2 (en) | 2015-03-19 | 2019-01-01 | Heptares Therapeutics Limited | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor |
AU2016231951B2 (en) * | 2015-03-19 | 2020-04-09 | Heptares Therapeutics Limited | Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor |
WO2017021729A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limited | Muscarinic agonists |
US10548884B2 (en) | 2015-08-03 | 2020-02-04 | Heptares Therapeutics Limited | Muscarinic agonists |
US10351545B2 (en) | 2015-08-03 | 2019-07-16 | Heptares Therapeutics Limited | Muscarinic agonists |
WO2017021728A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limted | Muscarinic agonists |
WO2017021730A1 (en) * | 2015-08-03 | 2017-02-09 | Heptares Therapeutics Limited | Muscarinic agonists |
US10167272B2 (en) | 2015-08-03 | 2019-01-01 | Heptares Therapeutics Limited | Muscarinic agonists |
EP3822262A1 (en) | 2015-08-03 | 2021-05-19 | Heptares Therapeutics Limited | Muscarinic agonists |
US11324738B2 (en) | 2015-08-03 | 2022-05-10 | Heptares Therapeutics Limited | Muscarinic agonists |
US11091456B2 (en) | 2015-08-03 | 2021-08-17 | Heptares Therapeutics Limited | Muscarinic agonists |
US10738029B2 (en) | 2015-08-03 | 2020-08-11 | Heptares Therapeutics Limited | Muscarinic agonists |
US11254656B2 (en) | 2015-08-03 | 2022-02-22 | Heptares Therapeutics Limited | Muscarinic agonists |
RU2737158C2 (en) * | 2015-08-03 | 2020-11-25 | Хептерс Терапьютикс Лимитед | Muscarinic receptor agonists |
US11208396B2 (en) | 2015-11-02 | 2021-12-28 | Heptares Therapeutics Limited | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor |
AU2016348847B2 (en) * | 2015-11-02 | 2021-07-08 | Heptares Therapeutics Limited | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor |
EP3797778A1 (en) * | 2015-11-02 | 2021-03-31 | Heptares Therapeutics Limited | Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor |
WO2017077292A1 (en) * | 2015-11-02 | 2017-05-11 | Heptares Therapeutics Limited | Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor |
US11834407B2 (en) | 2016-10-14 | 2023-12-05 | Heptares Therapeutics Limited | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists |
US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
US11773090B2 (en) | 2018-06-22 | 2023-10-03 | Heptares Therapeutics Limited | Pharmaceutical compounds |
US11945801B2 (en) | 2018-12-07 | 2024-04-02 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists |
US11999745B2 (en) | 2020-12-18 | 2024-06-04 | Heptares Therapeutics Limited | Pharmaceutical compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11793817B2 (en) | Muscarinic M1 receptor agonists | |
EP2897948B1 (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
AU2016348847B2 (en) | Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor | |
AU2016304387B2 (en) | Muscarinic agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12794751 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014541757 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2856076 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14358984 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012338581 Country of ref document: AU Date of ref document: 20121116 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1410398 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20121116 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012794751 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012794751 Country of ref document: EP Ref document number: 1410398.0 Country of ref document: GB |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014012056 Country of ref document: BR |
|
ENPC | Correction to former announcement of entry into national phase, pct application did not enter into the national phase |
Ref country code: GB |
|
ENP | Entry into the national phase |
Ref document number: 112014012056 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140519 |
|
ENPC | Correction to former announcement of entry into national phase, pct application did not enter into the national phase |
Ref country code: BR Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2423 DE 13/06/2017 POR TER SIDO INDEVIDA. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112014012056 Country of ref document: BR Kind code of ref document: A8 Free format text: REGULARIZE A CESSAO DA PRIORIDADE US 61/632,813 DE 18/11/2011, VISTO QUE OS DOCUMENTOS DE CESSAO APRESENTADOS FAZEM RESPEITO APENAS A CESSAO DO PEDIDO US 13/299,479. CUMPRE FRISAR QUE O DOCUMENTO DE CESSAO DEVE SER ESPECIFICO DA CITADA PRIORIDADE. |
|
ENP | Entry into the national phase |
Ref document number: 112014012056 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140519 |